CHITOCHOL: Metabolic Effect of an Innovative Chitosan Formulation
Study Details
Study Description
Brief Summary
Chitosan is a natural polysaccharide of β-1,4-linked glucosamine residues deriving from chitin, a dietary fiber primarily obtained from fungal cell walls and the exoskeletons of various crustaceans (e.g. crab, lobster, and shrimp) and whose cholesterol-lowering properties are due to the hydrophobic bonds it forms with cholesterol and other sterols, interfering with the emulsification process in the intestine.
In addition to reducing low-density lipoprotein cholesterol (LDL-C) levels, several studies showed that chitosan administration may help reduce body weight. For this reason, its use might be particularly useful as a strategy to simultaneously control two different risk factors for the development of CVDs.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: Active treatment Medical Device (Kaptufat®) |
Device: Medical Device (Kaptufat®)
140 mg chitosan, 460 mg cellulose and 35.384 mg ascorbic acid for 1 tablet
Oral administration: 3 tablets twice a day before the main meals
|
Placebo Comparator: Placebo Placebo |
Other: Placebo
Oral administration: 3 tablets twice a day before the main meals
|
Outcome Measures
Primary Outcome Measures
- Absolute change in LDL-C from baseline and between groups [12 weeks]
Absolute change in LDL-C after 12 weeks of treatment with MD compared to placebo
Secondary Outcome Measures
- Absolute change in LDL-C from baseline and between groups [6 weeks]
Absolute change in LDL-C from baseline and between groups after 6 weeks of treatment with MD compared to placebo
- Absolute change in serum lipids other than LDL-C (TC, TG, HDL-C, non-HDL-C) and apolipoproteins from baseline and between groups [12 weeks]
Absolute change in serum lipids other than LDL-C (TC, TG, HDL-C, non-HDL-C) and apolipoproteins from baseline and between groups after 12 weeks of treatment with MD compared to placebo
- Absolute change in serum lipids other than LDL-C (TC, TG, HDL-C, non-HDL-C) and apolipoproteins from baseline and between groups [6 weeks]
Absolute change in serum lipids other than LDL-C (TC, TG, HDL-C, non-HDL-C) and apolipoproteins from baseline and between groups after 6 weeks of treatment with MD compared to placebo
- Absolute change in lipids ratios from baseline and between groups [6 weeks]
Absolute change in lipids ratios from baseline and between groups after 6 weeks of treatment with MD compared to placebo
- Absolute change in lipid accumulation product (LAP) from baseline and between groups [6 weeks]
Absolute change in LAP from baseline and between groups after 6 weeks of treatment with MD compared to placebo
- Absolute change in lipids ratios from baseline and between groups [12 weeks]
Absolute change in lipids ratios from baseline and between groups after 12 weeks of treatment with MD compared to placebo
- Absolute change in LAP from baseline and between groups [12 weeks]
Absolute change in LAP from baseline and between groups after 12 weeks of treatment with MD compared to placebo
- Absolute change in fasting plasma glucose (FPG) from baseline and between groups [12 weeks]
Absolute change in FPG from baseline and between groups after 12 weeks of treatment with MD compared to placebo
- Absolute change in fasting plasma insulin from baseline and between groups [12 weeks]
Absolute change in fasting plasma insulin from baseline and between groups after 12 weeks of treatment with MD compared to placebo
- Absolute change in fasting plasma glucose (FPG) from baseline and between groups [6 weeks]
Absolute change in FPG from baseline and between groups after 6 weeks of treatment with MD compared to placebo
- Absolute change in fasting insulin from baseline and between groups [6 weeks]
Absolute change in fasting insulin from baseline and between groups after 6 weeks of treatment with MD compared to placebo
- Absolute change in homeostatic model assessment for insuline resistance (HOMA-IR) index from baseline and between groups [6 weeks]
Absolute change in HOMA-IR index from baseline and between groups after 6 weeks of treatment with MD compared to placebo
- Absolute change in HOMA-IR index from baseline and between groups [12 weeks]
Absolute change in HOMA-IR index from baseline and between groups after 12 weeks of treatment with MD compared to placebo
- Absolute change in weight from baseline and between groups [12 weeks]
Absolute change in weight from baseline and between groups after 12 weeks of treatment with MD compared to placebo
- Absolute change in weight from baseline and between groups [6 weeks]
Absolute change in weight from baseline and between groups after 6 weeks of treatment with MD compared to placebo
- Absolute change in waist circumference from baseline and between groups [6 weeks]
Absolute change in waist circumference from baseline and between groups after 6 weeks of treatment with MD compared to placebo
- Absolute change in waist circumference from baseline and between groups [12 weeks]
Absolute change in waist circumference from baseline and between groups after 12 weeks of treatment with MD compared to placebo
- Absolute change in body mass index (BMI) from baseline and between groups [12 weeks]
Absolute change in BMI from baseline and between groups after 12 weeks of treatment with MD compared to placebo
- Absolute change in body mass index (BMI) from baseline and between groups [6 weeks]
Absolute change in BMI from baseline and between groups after 6 weeks of treatment with MD compared to placebo
- Absolute change in index of visceral adiposity index (VAI) from baseline and between groups [6 weeks]
Absolute change in VAI from baseline and between groups after 6 weeks of treatment with MD compared to placebo
- Absolute change in index of central obesity (ICO) from baseline and between groups [6 weeks]
Absolute change in ICO from baseline and between groups after 6 weeks of treatment with MD compared to placebo
- Absolute change in index of central obesity (ICO) from baseline and between groups [12 weeks]
Absolute change in ICO from baseline and between groups after 12 weeks of treatment with MD compared to placebo
- Absolute change in index of visceral adiposity index (VAI) from baseline and between groups [12 weeks]
Absolute change in VAI from baseline and between groups after 12 weeks of treatment with MD compared to placebo
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subjects agree to participate in the study and having dated and signed the informed consent form;
-
Subjects who have the capability to communicate, to make themselves understood, and to comply with the study's requirements;
-
Male or female aged ≥ 18 years and ≤ 70 years old;
-
Subjects free from cardiovascular diseases (CVDs) (primary prevention for CVDs);
-
Subjects with sub-optimal serum levels of cholesterol (total cholesterol (TC) of 200-240 mg/dl OR LDL-C of 130-190 mg/dl);
-
Subjects with body mass index (BMI) 25 -34.9 Kg/m2
Exclusion Criteria:
-
Subjects already affected by CVDs (secondary prevention for CVDs);
-
Subjects with serum levels of triglycerides (TG)> 400 mg/dl;
-
Type 1 or type 2 diabetes;
-
Lipid-lowering treatment not stabilized since at least 2 months;
-
Known current gastrointestinal diseases and use of medications for their treatment;
-
Known clinically relevant decline in renal function;
-
Women in fertile age not using consolidated contraceptive methods
-
Pregnancy and Breastfeeding;
-
History or clinical evidence of any significant concomitant disease that could compromise the safety of the subject or the possibility of completing the study;
-
Any medical or surgical condition that would limit the patient adhesion to the study protocol
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | AOU Policlinico S.Orsola-Malpighi | Bologna | Italy |
Sponsors and Collaborators
- University of Bologna
Investigators
- Principal Investigator: Arrigo F.G. Cicero, MD, PhD, AOU Policlinico S. Orsola-Malpighi
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Chito_RCT2022